Skip to main content

Coffee Slows Progression of Hep C Liver Disease - AIDSMEDS.com

1 reply [Last post]
John
John's picture
Offline
Last seen: 1 day 17 hours ago
Joined: 09/03/2008

Coffee Slows Progression of Hep C Liver Disease

People living with chronic hepatitis C virus (HCV) infection and advanced liver disease who drink three or more cups of coffee per day have a 53 percent lower risk of liver disease progression than non-coffee drinkers, according to a new study published in the November issue of Hepatology. According to the paper, authored by Neal Freedman, PhD, MPH, of the National Cancer Institute and his colleagues, patients with hepatitis C–related bridging fibrosis or cirrhosis who did not respond to standard treatment benefited from increased coffee intake.

This study included 766 participants enrolled in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) trial who had hepatitis C–related bridging fibrosis or cirrhosis and failed to respond to standard treatment with pegylated interferon and ribavirin. Upon entering the study, HALT-C volunteers were asked to report their typical frequency of coffee intake and portion size over the past year. A similar question was asked for black and green tea intake.

Participants were seen every three months during the 3.8–year study period to assess clinical outcomes that included: ascites (abnormal accumulation of fluid in the abdomen), prognosis of chronic liver disease, death related to liver disease, hepatic encephalopathy (brain and nervous system damage), hepatocellular carcinoma (liver cancer), spontaneous bacterial peritonitis, variceal hemorrhage and/or increase in fibrosis. Liver biopsies were also taken at 1.5 and 3.5 years to determine the progression of liver disease.

Results showed that participants who drank three or more cups of coffee per day had a relative risk (RR) of 0.47 for reaching one of the clinical outcomes. An RR above 1.00 suggests an increase in the risk of disease progression, whereas an RR below 1.00 suggests a decrease in the risk of disease progression.

Researchers did not observe any association between tea intake and liver disease progression, though tea consumption was low in the study.

“Given the large number of people affected by HCV, it is important to identify modifiable risk factors associated with the progression of liver disease,” Freedman said. “Although we cannot rule out a possible role for other factors that go along with drinking coffee, results from our study suggest that patients with high coffee intake had a lower risk of disease progression.”

Results from this study should not be generalized to healthier populations, the authors cautioned.

Click here for original story and to make/read comments to it.

John
John's picture
Offline
Last seen: 1 day 17 hours ago
Joined: 09/03/2008
Coffee reduces side-effects in people on hep C treatment

Coffee consumption reduces side-effects in people on hepatitis C treatment

Author : Gus Cairns, Editor - HIV Treatment Update (HTU)

Published: 14 September 2011
 

Drinking three or more cups of coffee a day reduced the incidence of self-reported side effects by more than 80% compared to non-coffee drinkers in people co-infected with hepatitis C and HIV who were taking hepatitis C treatment, a French study has found.

The study adds to evidence that coffee could be a useful and cheap 'supplement' for people taking hepatitis C treatment and could considerably increase the rate of treatment success. A study published in June (Freedman) found that in patients with hepatitis C and not HIV, drinking three or more cups of coffee a day increased the likelihood of treatment success by 80%.

The HEPAVIH ANRS CO13 study is a cohort study of hepatitis C/HIV co-infected patients taking pegylated interferon/ribavirin hepatitis C therapy. For the present study, 106 patients were evaluated.

Patients were asked whether they drank coffee and if so, whether they drank it occasionally or had one, two or three or more cups of coffee a day. They were also asked to report on whether they had experienced a list of 30 different symptoms that have been reported as side-effects of hepatitis treatment and to rate the degree of distress they caused.

Seventy-five (71%) of the patients were men, their average age was 44 and 80% had been infected with both hepatitis C and HIV through injecting drugs.

At the start of the study 86% of the patients were taking HIV treatment and had an undetectable HIV viral load, although 13% had a CD4 count below 200 cells/mm3. More than half (52%) of patients had severe liver fibrosis or cirrhosis (fibrosis grades 3-4).

The median number of self-reported treatment side effects at baseline was three; 31% reported no side effects and 25% reported over eight.

Patients drinking three or more cups of coffee a day were 81% less likely to report discomforting side-effects than patients reporting none. The likelihood of reporting side-effects decreased by one-third (33%) between each category of coffee consumption (i.e. occasional drinkers had 33% fewer side-effects than non-drinkers, patients drinking one cup a day had 33% fewer than occasional drinkers, and so on).

After adjusting for gender, age and history of opioid use, which are known correlates of reporting a higher number of discomforting side-effects, the effect of coffee remained significant (36% decrease per increase in number of cups drunk).

The researchers comment that the effects seen could be due to caffeine combating the fatigue and lack of concentration and alertness often reported by patients receiving HCV treatment. However It is already known that drinking large amounts of coffee is associated with lower levels of liver enzymes and slower progression of pre-existing liver disease, and previous studies have reported no benefit in drinking tea, which also contains caffeine, albeit at lower levels. The researchers suggest further research into the benefits of coffee consumption and/or caffeine.

Reference

Spire B et al. Coffee consumption and side-effects relief during HCV treatment (ANRS CO13 HEPAVIH): a possible research hypothesis. Tenth AIDS Impact conference, Santa Fe, New Mexico. Abstract 81. 2011.

 

Note. Gus edit's HIV Treatment Update (HTU) which is published Quarterly with updates concerning HIV and related matters. You can read it online (click here) or to recieve it via the post provide your name and address to info@nam.org.uk . It is posted under plain cover.

You help save money for NAM by using the online version of HIV Treatment Update and the other resources thus enabling there funds to be spent on keeping us all up to date with HIV issues.

Post new comment

The content of this field is kept private and will not be shown publicly.
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
X
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Loading